KRAS and neoplasm: Previous studies reported that approximately 10–11% of advanced colorectal cancers showed intratumoral heterogeneity of KRAS or BRAF mutations where mutations were identified in only one of the multiple formalin‐fixed, paraffin‐embedded tumor blocks (Nelson et al., 2018; Richman et al., 2011).